Candidiasis - Pipeline Review, Q4 2010

Global Markets Direct, December 2010, Pages: 33

Candidiasis - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Candidiasis Pipeline Review, Q4 2010”, provides an overview of the Candidiasis therapeutic pipeline. This report provides information on the therapeutic development for Candidiasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Candidiasis. “Candidiasis-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Candidiasis.
- A review of the Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Candidiasis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Candidiasis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Candidiasis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Candidiasis Overview
Therapeutics Development
An Overview of Pipeline Products for Candidiasis
Candidiasis Therapeutics under Development by Companies
Candidiasis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Candidiasis Therapeutics Development
BioDelivery Sciences International, Inc.
Almirall, S.A.
Evolva SA
Universities/Institutes Involved in Candidiasis Therapeutics Development
Candidiasis Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Universities/Institutes
Anidulafungin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anidulafungin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Caspofungin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluconazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Fungal Infections – Pipeline Review, H1 2013
• Nausea – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Ebola Viral Infections – Pipeline Review, H1 2013
• HIV / AIDS – Pipeline Review, H1 2013
• Psychosis – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Liver Transplantation – Pipeline Review, H1 2013
• Natural Killer Cell Lymphomas – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013